Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: A pilot study

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 540-547

  Castellino, Sharon M ^a   Tooze, Janet A ^a   Flowers, Lynn ^a   Hill, Debbie F ^a   McMullen, Kevin P ^a   Shaw, Edward G ^a   Parsons, Susan K ^b,c  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

AChe inhibitor; Childhood brain tumor; Donepezil; Executive function; Survivors

Indexed keywords

DONEPEZIL;

ADOLESCENT; ANOREXIA; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVOR; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DELLIS KAPLAN EXECUTIVE FUNCTION TOWER TEST; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SCHOOL CHILD; TASK PERFORMANCE; TREATMENT OUTCOME; URINE INCONTINENCE; VISUAL MEMORY; VOMITING; WIDE RANGE ASSESSMENT OF MEMORY AND LEARNING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; INDANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PIPERIDINES; SURVIVORS; TREATMENT OUTCOME;

EID: 84863858224     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24078     Document Type: Article

References (44)

1. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the united states. Cancer Epidemiol Biomarkers Prev 2009; 18: 1033-1040.
2. Nathan PC, Patel SK, Dilley K, et al. Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: A report from the children's oncology group. Arch Pediatr Adolesc Med 2007; 161: 798-806.
3. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5: 399-408.
4. Bhat SR, Goodwin TL, Burwinkle TM, et al. Profile of daily life in children with brain tumors: An assessment of health-related quality of life. J Clin Oncol 2005; 23: 5493-5500.
5. Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: A report from the childhood cancer survivor study. J Clin Oncol 2004; 22: 999-1006.
6. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10: 293-310.
7. Butler RW, Copeland DR. Attentional processes and their remediation in children treated for cancer: A literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 2002; 8: 115-124.
8. Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001; 19: 1802-1808.
9. Mulhern RK, White HA, Glass JO, et al. Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 2004; 10: 180-189.
10. Conklin HM, Khan RB, Reddick WE, et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: A randomized, double-blind, cross-over trial. J Pediatr Psychol 2007; 32: 1127-1139.
11. Conklin HM, Lawford J, Jasper BW, et al. Side effects of methylphenidate in childhood cancer survivors: A randomized placebo-controlled trial. Pediatrics 2009; 124: 226-233.
12. Bowen DM, Francis PT, Pangalos MN, et al. Treatment strategies for alzheimer's disease. Lancet 1992; 339: 132-133.
13. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
14. Kishnani PS, Sullivan JA, Spiridigliozzi GA, et al. Donepezil use in down syndrome. Arch Neurol 2004; 61: 605-606.
15. Spiridigliozzi GA, Heller JH, Crissman BG, et al. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with down syndrome: A clinical report series. Am J Med Genet A 2007; 143A: 1408-1413.
16. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002; 12: 237-241.
17. Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 2004; 226: 63-66.
18. Handen BL, Johnson CR, McAuliffe-Bellin S, et al. Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures. J Child Adolesc Psychopharmacol 2011; 21: 43-50.
19. Reddick WE, White HA, Glass JO, et al. Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 2003; 97: 2512-2519.
20. Shaw EG, Rosdhal R, D'Agostino RB, et al. A phase ii study of donepezil in irradiated brain tumor patients: Effect on health-related quality of life and mood. Neuro-oncol 2004; 6: 357.
21. Delis D, Kaplan E, Kramer J. Delis-kaplan executive function scale. San Antonio, TX: The Psychological Corporation; 2001.
22. Sheslow D, Adams W. Wide range assessment of memory and learning, 2nd edition. Wilmington, DE: Wide Range, Inc.; 2003.
23. Conners C. Conner's continuous performance test (CPTII). North Tonawanda, NY: Multi-Health Systems, Inc.; 2004.
24. Weschler D. Weschler intelligence scale for children. San Antonio, TX: The Psychological Corporation; 2003.
25. Woodcock R. Woodcock johnson reading mastery-revised, normative update. Pines, MN: American Guidance Service; 1998.
26. Mather N, Woodcock R. Woodcock-johnson III tests of achievement. Itasca, IL: Riverside Publishing; 2001.
27. Gioia G, Isquith P, Guy S, et al. Behavior rating inventory of executive function. Psychological Assessment Resources, Inc; 2000.
28. Reynolds C, Camphaus R. Behavior assessment system for children, second edition. Pines, MN: American Guidance Service; 2004.
29. Stein RE, Jessop DJ. The impact on family scale revisited: Further psychometric data. J Dev Behav Pediatr 2003; 24: 9-16.
30. Varni JW, Seid M, Kurtin PS. Pedsql 4.0: Reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med care 2001; 39: 800-812.
31. Tao ML, Masterman-Smith M, Garvie PA, et al. Quality of life assessment (QUOLA) in pediatric brain tumor population: Feasibility and instrument properties of a new brain-specific instrument. Neuro Oncol 2004; 6: 448.
32. Cancer therapy evaluation program. Common terminology criteria for adverse events, version 3.0. Bethesda, MD: National Cancer Institute; 2003.
33. Parsons SK, Shih MC, Mayer DK, et al. Preliminary psychometric evaluation of the child health ratings inventory (chris) and disease-specific impairment inventory-hematopoietic stem cell transplantation (dsii-hsct) in parents and children. Qual Life Res 2005; 14: 1613-1625.
34. Cohen J. Statistical power analysis for the behavioral sciences Hillsdale. NJ: Lawrence Erlbaum; 1988.
35. Castellino SM, Tooze JA, Flowers L, et al. The peabody picture vocabulary test as a pre-screening tool for global cognitive functioning in childhood brain tumor survivors. J Neurooncol 2011; 104: 559-563.
36. Kazak AE, Simms S, Alderfer MA, et al. Feasibility and preliminary outcomes from a pilot study of a brief psychological intervention for families of children newly diagnosed with cancer. J Pediatr Psychol 2005; 30: 644-655.
37. Kishnani PS, Heller JH, Spiridigliozzi GA, et al. Donepezil for treatment of cognitive dysfunction in children with down syndrome aged 10-17. Am J Med Genet A 2010; 152A: 3028-3035.
38. Unguru Y. The successful integration of research and care: How pediatric oncology became the subspecialty in which research defines the standard of care. Pediatr Blood Cancer 2011; 56: 1019-1025.
39. Patel SK, Katz ER, Richardson R, et al. Cognitive and problem solving training in children with cancer: A pilot project. J Pediatr Hematol Oncol 2009; 31: 670-677.
40. Butler RW, Copeland DR, Fairclough DL, et al. A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy. J Consult Clin Psychol 2008; 76: 367-378.
41. Jasper BW, Conklin HM, Lawford J, et al. Growth effects of methylphenidate among childhood cancer survivors: A 12-month case-matched open-label study. Pediatr Blood Cancer 2009; 52: 39-43.
42. Alvarez JA, Emory E. Executive function and the frontal lobes: A meta-analytic review. Neuropsychol Rev 2006; 16: 17-42.
43. Gioia GA, Kenworthy Lisquith PK. Executive function in the real world: Brief lessons from mark ylvisaker. J Head Trauma Rehabilitat 2010; 25: 433-439.
44. TM). San Antonio, TX: Harcourt Assessment Inc; 1999.